GenoMed Adds Dr. Richard Reece to Business Development Advisory Board
Posted on: Monday, 22 August 2005, 09:01 CDT
ST. LOUIS, Aug. 22 /PRNewswire-FirstCall/ -- GenoMed, Inc. ("the Company" or "GenoMed") (Pinksheets: GMED) announced today the addition of Dr. Richard Reece, a prolific and influential medical writer, to its Business Development Advisory Board.
Dr. Richard Reece is a pathologist, writer, editor, and author. He has served as editor-in-chief of Physician Practice Options, a monthly newsletter for practicing physicians for nine years. The newsletter has variations that reach cardiologists, nephrologists, and oncologists. He is the author of four books. The latest is Voices of Health Reform (Practice Support Resources, Inc, 2005) consisting of 41 interviews with leading health care authorities. He also writes frequently for Healthleaders.com, which is read by 50,000 health care leaders each day. He serves on the advisory boards of the Center for Practical Health Reform and America's Top Doctors, a 1300 page book listing America's top doctors, based on nominations of other doctors.
Said Dr. David Moskowitz, GenoMed's Chairman and CEO, "Dr. Reece is a leader in developing practical approaches to health care reform, including consumer-directed healthcare. We are honored to have his help in crafting and delivering GenoMed's message of cost control and quality improvement to medical societies, health plans, and business coalitions."
About GenoMed(TM)
GenoMed, Inc. is a Next Generation DM(TM) company whose mission is to improve patient outcomes by identifying the molecular pathways or genes that cause disease. A St. Louis Business Journal article ( http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html ) first reported that the company applied for patents based on its finding that the ACE gene is associated with many common diseases. The company is currently marketing its protocols for preventing kidney failure due to diabetes and high blood pressure, and delaying the progression of emphysema. The company is also conducting a free clinical trial for West Nile virus; to enroll, simply click on the West Nile virus link at http://www.genomed.com/ .
Safe Harbor Statement
This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) treatments. The words or phrases "ought to,""should,""may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
GenoMed, Inc.
CONTACT: David Moskowitz, MD FACP, of GenoMed, Inc., +1-314-983-9933,dwmoskowitz@genomed.com
Web site: http://www.genomedics.com/
Source: PRNewswire-FirstCall
Related Articles
- Democratic National Committee Chairman Tim Kaine Issues Statement Following Senate Finance Committee's Vote to Pass Health Insurance Reform
- Genomic Health to Present at 19th Annual Piper Jaffray Health Care Conference
- Genomic Health Reports Inclusion of Oncotype DX(TM) in American Society of Clinical Oncology Guidelines
- Genomic Health, Inc. Announces Oncotype DX(TM) Recurrence Score(TM) Influences Treatment Decisions for Physicians and Patients in Prospective Study
- The National Surgical Adjuvant Breast and Bowel Project (NSABP) and Genomic Health Announce Study Results Demonstrating Precision of Oncotype DX(TM) in Measuring Estrogen Receptor Status
- Genomic Health to Present at the 18th Annual Piper Jaffray Health Care Conference
- Genomic Health, Inc. Announces Positive Results in Multiple Studies Presented at the American Society of Clinical Oncology Meeting
- The National Surgical Adjuvant Breast and Bowel Project (NSABP) and Genomic Health, Inc. Announce Positive Early Results in Development of Genomic Test for Colon Cancer Prognosis
- Genomic Health Announces Appointment of Dr. Woodrow Myers to Board of Directors
- Genomic Health Announces Study Results Demonstrating Oncotype DX(TM) Changed Adjuvant Treatment Approach for 25 Percent of Early-Stage Breast Cancer Patients
 |
 |
User Comments (0)
RSS Feeds